[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Armata Pharmaceuticals Inc (ARMP)

Armata Pharmaceuticals Inc (ARMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 295,523
  • Shares Outstanding, K 36,711
  • Annual Sales, $ 4,900 K
  • Annual Income, $ -173,800 K
  • EBIT $ -31 M
  • EBITDA $ -30 M
  • 60-Month Beta 1.31
  • Price/Sales 61.38
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 192.40% (+5.86%)
  • Historical Volatility 119.74%
  • IV Percentile 14%
  • IV Rank 13.21%
  • IV High 579.28% on 01/30/26
  • IV Low 133.50% on 09/04/25
  • Expected Move (DTE 32) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 6
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 124
  • Open Int (30-Day) 124
  • Expected Range 8.05 to 8.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.48
  • Number of Estimates 1
  • High Estimate $-0.48
  • Low Estimate $-0.48
  • Prior Year $-0.32
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.50 +7.33%
on 05/15/26
14.98 -46.26%
on 04/22/26
-4.01 (-33.25%)
since 04/15/26
3-Month
7.43 +8.34%
on 03/20/26
14.98 -46.26%
on 04/22/26
-0.10 (-1.23%)
since 02/13/26
52-Week
1.17 +588.03%
on 05/19/25
16.34 -50.73%
on 10/22/25
+6.65 (+475.00%)
since 05/15/25

Most Recent Stories

More News
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $25 million maturing in 2029

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02

Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"

Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors

LOS ANGELES , April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development...

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results

LOS ANGELES , March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development...

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus 

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3 study

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

LOS ANGELES , Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 8.05 (-1.83%)
Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

LOS ANGELES , Nov. 10, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity,...

ARMP : 8.05 (-1.83%)

Business Summary

Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including...

See More

Key Turning Points

3rd Resistance Point 9.71
2nd Resistance Point 9.16
1st Resistance Point 8.60
Last Price 8.05
1st Support Level 7.50
2nd Support Level 6.95
3rd Support Level 6.39

See More

52-Week High 16.34
Fibonacci 61.8% 10.55
Fibonacci 50% 8.76
Last Price 8.05
Fibonacci 38.2% 6.96
52-Week Low 1.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.